We found that ibrutinib treatment improved pulmonary edema and decreased the infiltration of inflammatory cells, neutrophils, and CD8+ T cell levels in lung tissues by regulating the BTK-, FLT3-, and EGFR-related signaling pathways to alleviate ALI in mice. This evidence concerns the gene EGFR and acute respiratory distress syndrome.